Predictmedix Inc. (PMED.CN)
CAD 0.03
(-14.29%)
CAD 0.03
(-14.29%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.81 Million CAD | 1.74% |
| 2022 | -1.9 Million CAD | -5.69% |
| 2021 | -1.8 Million CAD | 6.46% |
| 2020 | -1.86 Million CAD | -141.77% |
| 2019 | -2.27 Million CAD | -157.23% |
| 2018 | -309.91 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -219.37 Thousand CAD | 6.64% |
| 2024 Q1 | -234.96 Thousand CAD | 29.02% |
| 2023 Q4 | -331.01 Thousand CAD | 18.77% |
| 2023 FY | - CAD | 4.65% |
| 2023 Q1 | -430.41 Thousand CAD | 51.1% |
| 2023 Q3 | -407.5 Thousand CAD | 37.1% |
| 2023 Q2 | -647.88 Thousand CAD | -50.53% |
| 2022 Q2 | -332.88 Thousand CAD | -21.48% |
| 2022 FY | - CAD | -5.69% |
| 2022 Q4 | -880.12 Thousand CAD | -110.35% |
| 2022 Q3 | -418.41 Thousand CAD | -25.69% |
| 2022 Q1 | -274.01 Thousand CAD | 49.71% |
| 2021 FY | - CAD | 6.46% |
| 2021 Q2 | -381.97 Thousand CAD | 7.64% |
| 2021 Q1 | -413.57 Thousand CAD | 34.52% |
| 2021 Q3 | -462.5 Thousand CAD | -21.08% |
| 2021 Q4 | -544.84 Thousand CAD | -17.8% |
| 2020 FY | - CAD | -141.77% |
| 2020 Q1 | -330.37 Thousand CAD | -7.43% |
| 2020 Q3 | -492.96 Thousand CAD | -4.36% |
| 2020 Q2 | -472.39 Thousand CAD | -42.99% |
| 2020 Q4 | -631.59 Thousand CAD | -28.12% |
| 2019 Q4 | -307.52 Thousand CAD | -57.16% |
| 2019 Q3 | -195.67 Thousand CAD | -21.73% |
| 2019 Q1 | -123.1 Thousand CAD | -54.65% |
| 2019 FY | - CAD | -157.23% |
| 2019 Q2 | -160.74 Thousand CAD | -30.58% |
| 2018 Q3 | -114.94 Thousand CAD | -183.49% |
| 2018 FY | - CAD | 0.0% |
| 2018 Q4 | -79.59 Thousand CAD | 30.75% |
| 2018 Q2 | -40.54 Thousand CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aquarius Surgical Technologies Inc. | -456.62 Thousand CAD | -297.882% |
| Cannabix Technologies Inc. | -2.95 Million CAD | 38.432% |